Corrigendum to Assessing the Effect of Demographic Background on Barriers to Seek Medical Attention for Psoriasis [0.03%]
银屑病求医障碍与人口统计背景之间关系的评估的勘误子文章除了社会人口特征外,还有其他因素阻碍患者寻求牛皮癬治疗
[This corrects the article DOI: 10.1177/2475530320950265.]. © The Author(s) 2023.
Corrigendum to Prevalence of Utilization Management Policies Among the Psoriatic Disease Community: Results From the 2019 National Psoriasis Foundation Advocacy Survey [0.03%]
关于银屑病疾病社区中利用管理政策的流行性：来自2019年全国银屑病基金会倡导调查的结果的勘误表
[This corrects the article DOI: 10.1177/2475530320956602.]. © The Author(s) 2023.
Corrigendum to Practice Patterns of Palmoplantar Pustulosis: Patient Demographics and Treatment Options [0.03%]
掌跖脓疱病的治疗模式校正：患者的人口统计学特征及治疗选择
[This corrects the article DOI: 10.1177/24755303221099292.]. © The Author(s) 2023.
Corrigendum to Biologic Treatment of 4 HIV-Positive Patients: A Case Series and Literature Review [0.03%]
人类免疫缺陷病毒感染患者生物制剂治疗的订正：%s例患者的病例系列及文献复习
[This corrects the article DOI: 10.1177/2475530320954279.]. © The Author(s) 2023.
Corrigendum to Tildrakizumab Inadequate Responders Switching to an Alternative IL-23 Inhibitor: A Case Series [0.03%]
乌司奴单抗治疗不充分的患者换用另一种白细胞介素-23抑制剂：病例系列的勘误通知书
[This corrects the article DOI: 10.1177/24755303211037308.]. © The Author(s) 2023.
Corrigendum to Antibody Response to BNT162b2 Vaccine in Immune Modifiers-Treated Psoriatic Patients [0.03%]
英文学术论文 |免疫调节剂治疗银屑病患者对BNT162b2疫苗的抗体反应 纠正说明英文标题翻译为中文为“免疫调节剂治疗银屑病患者对BNT162b2疫苗的抗体反应（纠正说明）”
[This corrects the article DOI: 10.1177/24755303211056059.]. © The Author(s) 2023.
Corrigendum to Brodalumab for Treatment-Resistant Psoriasis: Case Reports and Safety Update [0.03%]
布罗利单抗治疗难治性银屑病的病例报告和安全性更新的勘误函
[This corrects the article DOI: 10.1177/2475530320925067.]. © The Author(s) 2023.
Corrigendum to Remission of Recalcitrant Psoriasis on Combined Biologic Therapy With Infliximab and Ustekinumab [0.03%]
关于英夫利昔单抗和乌司奴单抗联合治疗难治性银屑病缓解的勘误说明
[This corrects the article DOI: 10.1177/24755303211029598.]. © The Author(s) 2023.
Corrigendum to Retrospective Analysis in Patients With Moderate to Severe Plaque Psoriasis Treated With Tildrakizumab: Real-Life Clinical Data [0.03%]
关于艾那西普治疗中重度斑块型银屑病患者的回顾性分析：真实世界临床数据的勘误说明
[This corrects the article DOI: 10.1177/24755303221077211.]. © The Author(s) 2023.
Corrigendum to Treatment of Palmoplantar Pustulosis Using Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion: A Case Report [0.03%]
他扎罗汀联合霍巴胆甾醇乳膏治疗掌跖脓疱病的疗效观察——个案报告的更正通知
[This corrects the article DOI: 10.1177/2475530320950290.]. © The Author(s) 2023.